Skip to Main Content

French drug maker Genfit said Monday that its lead drug, elafibranor, failed to improve outcomes for patients with the fatty liver disease NASH, according to an interim analysis of a late-stage clinical trial.

“These results are highly disappointing,” Genfit CEO Pascal Prigent said in a statement. The company plans to review additional data and consult with regulators before determining if development of elafibranor should continue.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!